Incidence and Predictors of New-Onset Silent Atrial Fibrillation after Coronary Artery Bypass Graft Surgery
Table 1
Baseline characteristics according to the occurrence of atrial fibrillation.
(%), median (interquartile range),
SR group
Silent AF group
Clinical AF group
mean ± SD
()
()
()
Risk factors
Age, years
63 ± 9
65 ± 8
67 ± 9
0.09
Female sex
4 (8)
0 (0)
3 (14)
0.32
Systemic hypertension
43 (65)
8 (62)
13 (62)
0.95
Diabetes mellitus
25 (38)
5 (39)
6 (29)
0.73
Smoking
25 (38)
4 (31)
2 (10)
0.05
Obesity (BMI ≥ 30 kg/m²)
32 (48)
9 (70)
10 (48)
0.37
Hypercholesterolemia
50 (76)
10 (77)
17 (81)
0.89
Family history of CAD
28 (42)
7 (54)
11 (53)
0.61
Medical history
Recent MI
18 (27)
7 (54)
8 (38)
0.15
Previous peripheral arteriopathy
18 (27)
5 (39)
4 (19)
0.46
Previous sleep apnea
5 (8)
4 (31)
4 (19)
0.049
Previous treatments
Beta blockers
53 (80)
11 (85)
20 (95)
0.27
Calcium Channel Blockers
19 (29)
3 (23)
9 (43)
0.38
Diuretics
16 (24)
6 (46)
8 (38)
0.19
Statins
64 (97)
12 (92)
21 (100)
0.42
ACE inhibitors
54 (82)
10 (77)
18 (88)
0.81
VKA
3 (5)
1 (8)
1 (5)
0.89
Clinical data
NYHA > 1
31 (47)
6 (46)
9 (43)
0.95
CCS > 3
5 (8)
0
2 (10)
0.54
LVEF (%)
57 ± 11
55 ± 9
54 ± 14
0.44
LVEF < 45%
2 (3)
1 (8)
6 (29)
0.002
EuroSCORE
3 (1–5)
4 (2–6.5)
3 (2–6.5)
0.18
Logistic EuroSCORE
2.3 (1.4–3.7)
2.9 (1.5–5.2)
2.2 (1.4–6)
0.27
LA diameter
39.5 (35–43)
44 (37–46)
41 (36–44)
0.11
LA diameter > 45 mm
3 (5)
4 (36)
3 (16)
0.009
CHAD2DS2-VASc score > 1
44 (67)
10 (77)
16 (76)
0.59
Serum creatinine, mol/L
88 (74–102.5)
88 (80–101.5)
90 (76.5–101.5)
0.98
NT pro-BNP, pg/mL
146 (61–491)
156 (98–1852)
136 (75–533)
0.019
ACE indicates angiotensin conversion enzyme; AF: atrial fibrillation; BMI: body mass index; CAD: Coronary Artery Disease; CCS: Canadian cardiovascular society; LA: left atrial; LVEF: left ventricular ejection fraction; min: minutes; MI: myocardial infarction; NYHA: New York heart association; SD: standard deviation, SR: sinus rhythm; VKA: vitamin K antagonists. compared to SR group.
